IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.578
AS - Asia 1.916
EU - Europa 893
SA - Sud America 444
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 7
Totale 5.898
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.481
SG - Singapore 857
CN - Cina 457
IT - Italia 455
BR - Brasile 341
VN - Vietnam 218
IN - India 186
DE - Germania 100
SE - Svezia 100
GB - Regno Unito 79
CA - Canada 62
AR - Argentina 42
BD - Bangladesh 42
HK - Hong Kong 39
FI - Finlandia 34
NL - Olanda 22
MX - Messico 21
EC - Ecuador 20
FR - Francia 20
EU - Europa 18
JP - Giappone 18
RU - Federazione Russa 16
ID - Indonesia 14
RO - Romania 13
ES - Italia 12
IQ - Iraq 12
UA - Ucraina 12
ZA - Sudafrica 12
PK - Pakistan 10
CL - Cile 9
PY - Paraguay 9
TR - Turchia 9
VE - Venezuela 9
AT - Austria 7
CZ - Repubblica Ceca 7
JO - Giordania 7
TW - Taiwan 7
AU - Australia 6
CO - Colombia 6
UZ - Uzbekistan 6
EG - Egitto 5
IR - Iran 5
MA - Marocco 5
NP - Nepal 5
PE - Perù 5
PL - Polonia 4
SA - Arabia Saudita 4
TN - Tunisia 4
AZ - Azerbaigian 3
CH - Svizzera 3
DZ - Algeria 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
PA - Panama 3
UY - Uruguay 3
BW - Botswana 2
CG - Congo 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
KR - Corea 2
PH - Filippine 2
SN - Senegal 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
HN - Honduras 1
IE - Irlanda 1
IL - Israele 1
JM - Giamaica 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.898
Salva come PNG Salva come JPEG
Città #
San Jose 521
Singapore 290
Ashburn 241
Chandler 230
Dallas 169
Santa Clara 145
Hefei 126
Bengaluru 123
Milan 118
Lawrence 106
Princeton 106
Ho Chi Minh City 89
Beijing 74
Munich 59
Wilmington 58
Chicago 54
Catanzaro 49
London 49
Des Moines 40
Hong Kong 39
New York 38
Hanoi 37
Ottawa 28
São Paulo 28
Los Angeles 27
Turku 23
Council Bluffs 22
Brooklyn 18
Rome 16
Guangzhou 13
Montreal 13
Naples 13
Redwood City 13
Pune 12
Boardman 11
Da Nang 11
Helsinki 11
Rio de Janeiro 11
San Francisco 11
Shanghai 11
Tokyo 11
Haiphong 10
Redmond 10
The Dalles 10
Porto Alegre 9
Toronto 9
Biên Hòa 8
Columbus 8
Amman 7
Brasília 7
Charlotte 7
Guayaquil 7
Buffalo 6
Can Tho 6
Chennai 6
Cosenza 6
Horia 6
Jiaxing 6
Leawood 6
Manchester 6
Mountain View 6
Tashkent 6
Timisoara 6
Ahmedabad 5
Atlanta 5
Augusta 5
Baghdad 5
Belo Horizonte 5
Kulgam 5
Lima 5
Mexico City 5
Olomouc 5
Orem 5
Parma 5
Phoenix 5
Quito 5
Reggio Calabria 5
Salvador 5
San Nicola Manfredi 5
Zhengzhou 5
Ankara 4
Asunción 4
Bari 4
Berlin 4
Birigui 4
Curitiba 4
Dhaka 4
Florianópolis 4
Goiânia 4
Hanover 4
Jakarta 4
Norwalk 4
Paris 4
San Antonio 4
Santiago 4
Settingiano 4
Stockholm 4
Taoyuan District 4
Thái Bình 4
Thái Nguyên 4
Totale 3.387
Salva come PNG Salva come JPEG
Nome #
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations 166
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 143
miR-22 suppresses DNA ligase III addiction in multiple myeloma 103
Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study 94
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 83
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 79
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 77
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 75
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 74
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 74
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 73
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 71
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. 70
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 70
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 69
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 67
Enlarging the clinical spectrum of chorea-acanthocytosis 65
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia 63
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 63
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 62
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice 62
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
Mir-221/222 are promising targets for innovative anticancer therapy 60
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 60
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report. 59
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype 59
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 59
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 58
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 57
Role of Nucleophosmin in embryionic development and tumorigenesis 55
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 55
The non-coding RNA landscape of plasma cell dyscrasias 55
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma 55
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: Insights fromthe EYESHOT study 54
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 54
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 54
Mycosis fungoides and gastric t-cell lymphoma: A case report 54
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 53
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials 51
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 51
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 50
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 50
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy 49
Dendritic cells have the option to express IDO-mediated suppression or not 49
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 48
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 48
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 48
Human Dendritic Cells: Potent Antigen-Presenting Cells at the Crossroads of Innate and adaptive Immunity 48
Daunorubicina liposomiale in ematologia 47
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 47
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 47
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 45
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation) 45
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 44
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 44
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology 44
CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues 44
Mouse models of Multiple Myeloma: technologic platforms and perspectives 43
Immunologic microenvironment and personalized treatment in multiple myeloma 43
null 43
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 42
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 42
Translational Studies on the Bone Marrow Microenvironment in Multiple Myeloma: Experimental Models and Emerging Therapeutical Strategies 42
Multiple myeloma-related bone disease: state-of-art and future treatments 41
Osteonecrosis of the Jaw Prevention and Management in Modern Oncology 41
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 40
Emerging Role of MicroRNAs in the Pathophysiology of Immune System 40
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management? 40
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 40
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 39
Multiple Myeloma Cells downregulatemiR-29b in dendritic cells to promote a tumor permissive inflammatory microenvironment and immune escape 38
Molecular Targets for the Treatment of Multiple Myeloma 38
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients. 37
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells 37
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 37
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress 36
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials 36
CFD analysis of different arterial cannulation site during Heart Surgery with Cardioplumnonary Bypass 36
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 36
Primary large B-cell lymphoma involving the cerebellopontine angle mimic acoustic schwannoma: Role of MR Spectroscopy in differential diagnosis. A case report 35
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 35
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma 35
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 35
Enumeration of IL-10-positive B cells from peripheral blood of Chronic Lymphocytic Leukemia patients 35
MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile 35
Targeting miR-21 in bone marrow stromal cells restores RANKL/OPG ratio within multiple myeloma microenvironment 35
Non-Coding RNAs in multiple myeloma bone disease pathophysiology 35
MicroRNAs in multiple myeloma and related bone disease 35
Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia 34
Whole Body Magnetic Resonance and CT/PET in patients with multiple myeloma at staging and after treatment: personal experience in a longitudinal study 33
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches 32
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients 31
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome 30
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 30
miR-29b targets HDAC4 and mediates activity of HDAC inhibitors in multiple myeloma cells 30
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 29
MiR-29b Counteracts Aberrant HDAC4 Expression and Enhances Vorinostat Activity in Multiple Myeloma 29
Totale 5.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.956
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.956
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/2022319 9 4 4 72 36 17 10 58 25 30 48 6
2022/2023723 223 37 33 46 69 54 4 49 103 38 51 16
2023/2024325 74 44 23 18 26 87 8 7 2 9 13 14
2024/20251.375 190 93 67 69 96 167 30 40 142 69 144 268
2025/20263.005 142 280 315 583 308 109 399 178 357 209 83 42
Totale 6.052